Ciana Therapeutics is a clinical development-stage company led by an experienced team developing new therapies within ophthalmology and with an initial focus on Diabetic Retinopathy.

More than 463 million patients are living with diabetes. A serious complication of diabetes is Diabetic Retinopathy.

Diabetic Retinopathy damages the eyes in patients with diabetes and can lead to vision loss and blindness. This eye complication afflicts 125 million patients with diabetes globally – and 30 million people in the US and Europe alone.

Ciana’s therapy is based on Danegaptide – a drug that can both treat Diabetic Retinopathy and prevent disease progression.

Unlike the leading injectable eye therapies that only block VEGF and limit vascular edema, Danegaptide can stabilize cell-cell junctions in the retinal capillaries, protect from capillary loss, and prevent vascular leakage and edema.

Combatting vision loss and blindness in patients with diabetes